Table 3 Incidences of primary effectiveness outcomes in patients receiving THA
| Â | Fondaparinux | Enoxaparin | UFH | Others | Medication (-) | Total |
|---|---|---|---|---|---|---|
n = 261 (%) | n = 148 (%) | n = 32 (%) | n = 44 (%) | n = 383 (%) | n = 868 (%) | |
All venous thromboembolism | 17 (6.5) | 17 (11.5) | 5 (15.6) | 8 (18.2) | 62 (16.2) | 109 (12.6) |
  Any DVT (up to POD10 ) | 17 (6.5) | 17 (11.5) | 5 (15.6) | 8 (18.2) | 62 (16.2) | 109 (12.6) |
  Symptomatic DVT | 0 | 1 (0.7) | 0 | 0 | 1 (0.3) | 2 (0.2) |
   Distal | 0 | 1 (0.7) | 0 | 0 | 1 (0.3) | 2 (0.2) |
   Proximal | 0 | 0 | 0 | 0 | 0 | 0 |
  Non-symptomatic DVT | 17 (6.5) | 16 (10.8) | 5 (15.6) | 8 (18.2) | 61 (15.9) | 107 (12.3) |
   Distal | 15 (5.7) | 13 (8.8) | 3 (9.4) | 8 (18.2) | 51 (13.3) | 90 (10.4) |
   Proximal | 2 (0.8) | 3 (2.0) | 2 (6.3) | 0 | 10 (2.6) | 17 (2.0) |
  PE (up to POD28) | 0 | 0 | 0 | 0 | 0 | 0 |